共 50 条
Cytokines, Genetic Lesions and Signaling Pathways in Anaplastic Large Cell Lymphomas
被引:1
|作者:
Merlio, Jean-Philippe
[1
,2
]
Kadin, Marshall E.
[3
,4
]
机构:
[1] Ctr Hosp & Univ Bordeaux, Tumor Biol & Tumor Bank Lab, F-33600 Pessac, France
[2] Univ Bordeaux, INSERM U1053, F-33000 Bordeaux, France
[3] Brown Univ, Dept Pathol & Lab Med, Alpert Sch Med, Providence, RI 02903 USA
[4] Boston Univ, Dept Dermatol, Boston, MA 02215 USA
来源:
关键词:
anaplastic large cell lymphoma;
oncogenesis;
cytokine;
signaling pathways;
CD30(+) LYMPHOPROLIFERATIVE DISORDERS;
T-CELL;
BRENTUXIMAB VEDOTIN;
HODGKIN-LYMPHOMA;
TP63;
REARRANGEMENTS;
CUTANEOUS LYMPHOMA;
ALK;
EXPRESSION;
KINASE;
ACTIVATION;
D O I:
10.3390/cancers13174256
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Simple Summary This review summarizes the main features of anaplastic large cell lymphoma (ALCL) subtypes focusing on activated biological pathways that may have clinical significance for diagnosis, prognosis and personalized therapy. ALCL is a tumor of activated T cells and possibly innate lymphoid cells with several subtypes according to clinical presentation and genetic lesions. On one hand, the expression of transcription factors and cytokine receptors triggers signaling pathways. On the other hand, ALCL tumor cells also produce many proteins including chemokines, cytokines and growth factors that affect patient symptoms. Examples are accumulation of granulocytes stimulated by IL-8, IL-17, IL-9 and IL-13; epidermal hyperplasia and psoriasis-like skin lesions due to IL-22; and fever and weight loss in response to IL-6 and IFN-gamma. In this review, we focus on the biology of the main ALCL subtypes as the identification of signaling pathways and ALCL-derived cytokines offers opportunities for targeted therapies.
引用
收藏
页数:17
相关论文